A carregar...
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
BACKGROUND: Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC) formulations have been developed. Subcutaneous administration of mAbs can offer substantial...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3776971/ https://ncbi.nlm.nih.gov/pubmed/24002601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.371 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|